MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

26.16 +0.09 (+0.33%)
Delayed Quote Updated: 11:04 AM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke (STOK) Q3 2026 Earnings Call Transcript ↗
Dravet syndrome trial enrollment exceeded targets with zero discontinuations. 
Via The Motley Fool
Topics Earnings
News headline image
Stoke Therapeutics Q3 Earnings Call Highlights ↗
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a... 
Via MarketBeat
Topics Earnings
News headline image
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts ↗
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations... 
Via MarketBeat
News headline image
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript ↗
Phase III enrollment complete for zorevunersen with zero discontinuation rates. 
Via The Motley Fool
Topics Earnings
News headline image
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Q2 Earnings Call Highlights ↗
Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion... 
Via MarketBeat
Topics Earnings
News headline image
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Stoke Therapeutics
Via Business Wire
News headline image
Stoke Therapeutics Q1 Earnings Call Highlights ↗
Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year... 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story